Lee JS, et al. • Predictors of Treatment Response in Patients with COPD HC. International study of asthma and allergies in childhood (ISAAC): rationale and methods. Eur Respir J 1995; 8: 483-91. 11. Park JO, Choi IS, Park KO. Normal predicted standards of single breath carbon monoxide diffusing capacity of lung in healthy nonsmoking adults. Korean J Intern Med 1985; 28: 176-83. 12. Choi JK, Paek D, Lee JO. Normal predicted values of spirometry in Kore- an population. Tuberc Respir Dis 2005; 58: 230-42. 13. Quanjer P, Dalhuijsen A, Van Zoramen B. Standardized lung function testing. Report of the working party for the European Community for Coal and Steel. Bull Eur Physiopathol Respir 1983; 19 Suppl 5: 1-95. 14. Lee YK, Oh YM, Lee JH, Kim EK, Lee JH, Kim N, Seo JB, Lee SD; KOLD Study Group. Quantitative assessment of emphysema, air trapping, and airway thickening on computed tomography. Lung 2008; 186: 157-65. 15. Gevenois PA, de Maertelaer V, De Vuyst P, Zanen J, Yernault JC. Com- parison of computed density and macroscopic morphometry in pulmo- nary emphysema. Am J Respir Crit Care Med 1995; 152: 653-7. 16. Wood SA, Zerhouni EA, Hoford JD, Hoffman EA, Mitzner W. Measure- ment of three-dimensional lung tree structures by using computed tomog- raphy. J Appl Physiol 1995; 79: 1687-97. 17. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodi- lator reversibility testing in chronic obstructive pulmonary disease. Tho- rax 2003; 58: 659-64. 18. Calverley P, Pauwels RA, Jones PW, Anderson JA, Vestbos J. The severity of airways obstruction as a determinant of treatment response in COPD. Int J Chron Obstruct Pulmon Dis 2006; 1: 209-18. 19. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J. Efficacy of salmeterol/fluticasone propio- nate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59. 20. Meslier N, Charbonneau G, Racineux J. Wheezes. Eur Respir J 1995; 8: 1942-8. 21. Marini JJ, Pierson DJ, Hudson LD, Lakshminarayan S. The significance of wheezing in chronic airflow obstruction. Am Rev Respir Dis 1979; 120: 1069-72. 22. Chanez P, Vignola AM, O’Shaugnessy T, Enander I, Li D, Jeffery PK, Bousquet J. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997; 155: 1529-34. 23. Kitaguchi Y, Fujimoto K, Kubo K, Honda T. Characteristics of COPD phe- notypes classified according to the findings of HRCT. Respir Med 2006; 100: 1742-52. 24. Nakano Y, Muro S, Sakai H, Hirai T, Chin K, Tsukino M, Nishimura K, Itoh H, Paré PD, Hogg JC, Mishima M. Computed tomographic measure- ments of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med 2000; 162: 1102-8. 25. Boschetto P, Miniati M, Miotto D, Braccioni F, De Rosa E, Bononi I, Papi A, Saetta M, Fabbri LM, Mapp CE. Predominant emphysema phenotype in chronic obstructive pulmonary. Eur Respir J 2003; 21: 450-4. 26. Makita H, Nasuhara Y, Nagai K, Ito Y, Hasegawa M, Betsuyaku T, On- odera Y, Hizawa N, Nishimura M; Hokkaido COPD Cohort Study Group. Characterisation of phenotypes based on severity of emphysema in chron- ic obstructive pulmonary disease. Thorax 2007; 62: 932-7. 27. Lee JH, Lee YK, Kim EK, Kim TH, Huh JW, Kim WJ, Lee JH, Lee SM, Lee S, Lim SY, Shin TR, Yoon HI, Sheen SS, Kim N, Seo JB, Oh YM, Lee SD. Responses to inhaled long-acting beta-agonist and corticosteroid accord- ing to COPD subtype. Respir Med 2010; 104: 542-9. 28. Nakano Y, Wong JC, de Jong PA, Buzatu L, Nagao T, Coxson HO, Elliott WM, Hogg JC, Paré PD. The prediction of small airway dimensions using computed tomography. Am J Respir Crit Care Med 2005; 171: 142-6. 29. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Stolk J, Sont JK, Jansen DF, Kerstjens HA, Postma DS, Sterk PJ; Groningen and Leiden Univer- sities Corticosteroids in Obstructive Lung Disease Study Group. Disso- ciation of lung function and airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 499-504. 30. Han MK, Postma D, Mannino DM, Giardino ND, Buist S, Curtis JL, Mar- tinez FJ. Gender and chronic obstructive pulmonary disease: why it mat- ters. Am J Respir Crit Care Med 2007; 176: 1179-84. AUTHOR SUMMARY Predictors of Pulmonary Function Response to Treatment with Salmeterol/ fluticasone in Patients with Chronic Obstructive Pulmonary Disease Jae Seung Lee, Jin Won Huh, Eun Jin Chae, Joon Beom Seo, Seung Won Ra, Ji-Hyun Lee, Eun-Kyung Kim, Young Kyung Lee, Tae-Hyung Kim, Woo Jin Kim, Jin Hwa Lee, Sang-Min Lee, Sangyeub Lee, Seong Yong Lim, Tae Rim Shin, Ho Il Yoon, Seung Soo Sheen, Yeon-Mok Oh, and Sang-Do Lee Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease and their responses to combination therapy (inhaled corticosteroid [ICS] + long acting β2-agonist [LABA]) are variable. Currently, reliable predictors for the responsiveness of COPD patients to the combination therapy are lacking. Here we investigated the parameters of pulmonary function test and radiological findings in the COPD patients treated for 3 months with salmeterol and fluticasone. The results show that wheezing history, pre- bronchodilator pulmonary function, bronchodilator responsiveness, and emphysema extent may be used for predicting the pulmonary function response to 3 months of treatment with the combination therapy. DOI: 10.3346/jkms.2011.26.3.379 http://jkms.org 385